FCGRT and autoimmune thrombocytopenic purpura: FcRn blockade selectively lowers pathogenic IgG without impacting other immunoglobulins, a mechanism validated in clinical trials for autoimmune diseases like myasthenia gravis and ITP [14,15,49].